Background: The most common cause of chronic heart failure in the US is secondary or primary dilated cardiomyopathy (DCM). The DCM phenotype exhibits changes in the expression of genes that regulate contractile function and pathologic hypertrophy. However, it is unclear if any of these alterations in gene expression are disease producing or modifying. Materials and Methods: One approach to providing evidence for cause-effect of a disease-influencing gene is to quantitatively compare changes in phenotype to changes in gene expression by employing serial measurements in a longitudinal experimental design. We investigated the quantitative relationships between changes in gene expression and phenotype n 47 patients with idiopathic DCM. In endomyocardial biopsies at baseline and 6 months later, we measured mRNA expression of genes regulating contractile function (␤-adrenergic receptors, sarcoplasmic reticulum
Introduction
Disease phenotypes are ultimately the result of changes in gene expression. In the chronically failing hypertrophied human heart, selective changes in the expression of genes that could potentially modify phenotype have been reported (1-8), typically in explanted human hearts at the end stage of the disease process (1-6). Reported alterations in gene expression in this setting include changes in the mRNA or protein expression of components of ␤-adrenergic signal transduction (2) (3) (4) , calcium handling proteins (1,5), and contractile proteins (6) . However, in these studies it has been difficult to determine which alterations in gene expression are fundamentally related to contractile dysfunction as opposed to those which are epiphenomena associated with advanced disease. Another interpretative challenge in these studies has been the difficulty of distinguishing between adaptive versus maladaptive processes, because many of the described changes are products of compensatory mechanisms that can produce either benefit or harm.
Additionally, because end-stage failing hearts or the organ donor-procured controls used in these studies may be affected by a multitude of ancillary factors, it is important to ultimately investigate gene expression in the intact heart. In the intact heart, starting material can be obtained from less advanced myocardial failure and controls are not subjected to the profound homeostatic disruption of brain death (9) . Also, studies in the intact heart may be conducted longitudinally employing serial measurements (8, (10) (11) (12) , which theoretically allows for detection of gene expression changes more directly associated with phenotypic modification. Importantly, because gene regulation is combinatorial (13) , a strong case can be made for investigating previously described (7, 8) . Norepinephrine and epinephrine were determined in plasma from coronary sinus blood by a previously described radioenzymatic method (11) .
Left and Right Ventricular Ejection Fraction Measurements by Radionuclide Ventriculography
LVEF and right ventricular ejection fraction (RVEF) were measured by in vitro red blood cell labeling and imaging techniques as previously described (18, 20) , and the results were expressed in EF units ([stroke volume/end diastolic volume] ϫ 100). For RVEF a first-pass technique was employed, and for LVEF an equilibrium technique was used.
Statistical Analysis
The 45 subjects who had baseline and end-of-study mRNA measurements were rank ordered according to change in LVEF into three groups without regard to treatment type. For the 45 subjects who had baseline and end-of-study mRNA measurements, 15 subjects with an LVEF change from Ϫ11 and ϩ2 (average Ϫ2.2 Ϯ 1.1[standard error of the mean; SEM]) EF units comprised the Declined/No Change function group, 15 subjects with an LVEF change from ϩ5 and ϩ17 (average 12.2 Ϯ 0.9) EF units comprised the Improved group, and 15 subjects with changes from ϩ18 and ϩ44 (average 25.5 Ϯ 1.8) EF units comprised the Marked Improvement group. The 36 subjects who had baseline and end-of-study receptor protein measurements were also rank ordered by LVEF change. Eleven subjects comprised the Declined/No Change function group (average change Ϫ3.5 Ϯ 1.2 EF units, range Ϫ11 to ϩ1 EF units), 13 subjects were in the Improved group (average change 8.5 Ϯ 1.1 EF units, range 2-13 EF units), and 12 subjects were in the Marked Improvement group (average change 23.1 Ϯ 1.6 EF units, range [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] . We chose to rank order ventricular function change by LVEF rather than RVEF because (1) gene expression changes on the right side of the septum are closely related to those that occur in both the LV and RV free walls (6), presumably because the septum is a wall shared by both chambers, (2) with radionuclide techniques LVEF is more accurately measured than is RVEF (24) , (3) 14 of the 45 study subjects had normal (Ն40 EF units) RVEF values at baseline, and (4) as shown in Results, the ordered classification of LVEF changes also resulted in incrementally increasing RVEF changes.
Changes in receptor protein, mRNA, and other variables of interest among the three LV function change groups were analyzed by three methods. In the first method, in which the LV function change groups were treated as ordinal variables, the relationships between various interval-level outcome variables and the ordinal-level change in LVEF were assessed with an ordinal trend test. This test is analogous to a test of bivariate regression used to assess a dose-response relationship between two gene expression in intact tissues where the net effect of multiple regulatory influences can be assessed.
Using reverse transcription quantitative PCR (RT-QPCR), it is possible to measure the steadystate mRNA abundance of multiple genes in small amounts of starting material (14) , such as endomyocardial biopsy (1, 7, 8, 12, 15) . Treatment of chronic heart failure subjects with ␤-adrenergic blocking agents is associated with improvement in systolic function and a reversal of remodeling in the majority of subjects with a dilated phenotype (16) , within a time frame of 4 to 12 months (16) (17) (18) (19) (20) (21) that is amenable to serial investigation. This contrasts with the time course of the natural history of dilated cardiomyopathies, which is that of slow (time course of years) progression in phenotype and clinical sequelae (22, 23) . The current investigation is an analysis of the quantitative relationships between changes in phenotype and the expression of contractilityregulating or pathologic hypertrophy-associated genes in a subject population of idiopathic dilated cardiomyopathy (IDC) patients treated for 6 months with placebo or ␤-adrenergic blockade.
Methods

Clinical Protocol
This study was designed to investigate changes in gene expression associated with phenotypic modulation in IDC, irrespective of treatment. Fifty-three subjects with symptomatic IDC and left ventricular ejection fraction (LVEF) were randomized to 6 months treatment with placebo, metoprolol tartrate, or carvedilol. Details of this treatment protocol are published elsewhere (8) . Forty-nine subjects completed this protocol, and the current report concerns the 47 individuals who had complete (baseline and after 6 months of treatment) mRNA (n ϭ 45) or ␤-adrenergic receptor protein (n ϭ 36) measurements.
Right Ventricular Endomyocardial Biopsy and Right Heart Catheterization
Right heart catheterization and endomyocardial biopsy with allocation of tissue for mRNA and ␤-receptor protein measurements were performed from the right internal jugular vein as previously described (7, 8) .
Messenger RNA Expression Measurements in Endomyocardial Biopsy Material
Messenger RNA abundance for six different genes (␤ 1 -and ␤ 2 -adrenergic receptors, ␣-and ␤-myosin heavy chain [MyHC] , atrial natriuretic peptide [ANP] , and SR Ca 2ϩ ATPase [SERCA-2a or SRCA]) was quantified in extracted total RNA, by RT-PCR using previously described methods (7, 8) .
␤-Adrenergic Receptor Measurements in Endomyocardial Biopsy Material, Catecholamine Measurements
Total ␤-receptor density and ␤ 1 -and ␤ 2 -receptor subtypes were measured in biopsy material as moderate symptoms (majority NYHA Class III), severe LV dysfunction (mean LVEF 21.6 EF units), preserved resting hemodynamics (mean cardiac index 2.44 mL/min/m 2 ), mild volume overload (mean pulmonary wedge pressure 13.6 mm Hg, mean right atrial mean pressure 5.9 mm Hg), moderate exercise intolerance (mean peak VO 2 16.2 ml/kg/min), and marked cardiac adrenergic activation (mean coronary sinus norepinephrine 982 pg/ml). There were no differences in any baseline demographic measurement between subjects assigned to the three treatment groups.
Baseline Gene Expression Data
Baseline mRNA and ␤-receptor protein data in the 47 IDC subjects are reported elsewhere (8) and consisted of decreases in the mRNA and protein expression of ␤ 1 -adrenergic receptors, decreases in the mRNA expression of SRCA and ␣-MyHC genes, and a respective increase or trends for an increase in the mRNA expression of ANP and ␤-MyHC.
Effect of Treatment
Between-Group Changes By treatment group comparison the only statistically significant changes among groups were in LVEF, where by ANOVA the metoprolol and carvedilol groups exhibited greater numerical increases than the placebo group (that were not quite significant after Bonferroni multiple group correction), and peak exercise heart rate, where both ␤-blocker groups exhibited greater degrees of reduction ( Table 2) . A low p value for this contrast indicates substantial deviation from uniformity of the deltas. This analysis assumes only that each ascending class of LV function change is greater than the preceding one, and it is useful for detecting the presence of a systematic relationship between dependent and independent variables while making no assumptions about the quantitative nature of such a relationship.
In the second method, the relationship of changes in LV function to changes in the variables of interest was assessed by linear regression analysis, treating LVEF change as a continuous interval variable, with and without statistical adjustment for effect of treatment group. In the third method, the three LV function change groups were analyzed independently by ANOVA and the Bonferroni multiple comparison test, with the model adjusted to statistically control for any effect of treatment group.
Changes in measured parameters among the three treatment groups were assessed by ANOVA/ Bonferroni, and changes within treatment group by paired t test. LVEF and RVEF class differences among treatment groups were also assessed by contingency table analysis of the rank-ordered EF changes into Decline/No Change, Improved, and Marked Improvement groups. Changes in New York Heart Association (NYHA) class among LV function change groups were assessed by the Spearman rank correlation coefficient. Potential differences within functional change and treatment groups were assessed by Student's paired t test. Differences between baseline values in IDC subjects versus nonfailing controls were assessed by Student's unpaired t test. Baseline data are given with variance estimated as standard deviation, and changes are given with variance estimated as SEM. A two-sided p value Ͻ .05 was considered to be statistically significant. p values for the ordinal trend test, ANOVA, and linear regression were adjusted for the effect of treatment group. Table 1 gives the demographics and other clinical descriptors of the 47 subjects with heart failure from IDC that had complete (baseline and after 6 months of treatment) ventricular function and mRNA (n ϭ 45) or ␤-adrenergic receptor protein (n ϭ 36) measurements. The subject population is a relatively young (mean age 53 years) heart failure group with responses in the three LVEF change groups for subjects who had complete mRNA measurements. As shown in Table 3 , LVEF by definition and RVEF data exhibit sequential increases among the three LV function change groups. The only other hemodynamic variable listed in 
Results
Subject Demographics
positively related (r ϭ 0.51, p ϭ 0.001), and pulmonary artery mean pressure (r ϭ Ϫ0.37, p ϭ 0.029) was negatively related. No other hemodynamic changes were significantly related to change in LVEF.
Within-Group Changes
The Decline/No Change group exhibited a decrease in heart rate and an increase in stroke volume index. The Improved group
Within-Group Changes There were multiple significant (p Ͻ 0.05) changes in the measured parameters within treatment groups, as presented in Table 2 . The placebo group exhibited decreases in ANP mRNA abundance and coronary sinus or arterial norepinephrine, and an increase in ␤ 1 -adrenergic receptors percent. The metoprolol group had increases in total ␤-and ␤ 1 -adrenergic receptor densities, LVEF, RVEF, stroke volume, and LV stroke work indices, and decreases in peak exercise heart rate, NYHA class, and resting heart rate. In the carvedilol group, there were increases in total ␤-and ␤ 1 -adrenergic receptor density, LVEF, RVEF, stroke volume, and LV stroke work indices, and decreases in peak exercise heart rate, NYHA class, ANP mRNA abundance, pulmonary wedge mean pressure, pulmonary artery mean pressure, and resting heart rate. had increases in LVEF, RVEF, and stroke volume index, and a decrease in heart rate. The Marked Improvement group exhibited an increase in LVEF, RVEF, stroke volume index, and left ventricular stroke work index, and a decrease in pulmonary wedge mean pressure, pulmonary arterial mean pressure, and heart rate.
Changes in Hemodynamics
Changes in mRNA Expression by LV Function Change Group or Linear Regression Analysis of LVEF Change
Between-Group Changes Figures 1 through 4 give the changes in mRNA expression in the LV function change groups. As shown in Figure 1 , there were no changes in ␤-adrenergic receptor mRNA expression associated with changes in left ventricular function. There were also no changes in ␤ 1 -or ␤ 2 -adrenergic mRNA abundance within any of the function change groups. Similarly, Figure 2 demonstrates that SRCA and ANP gene expression is not different among the different functional groups.
In contrast, there were changes in both ␣-and ␤-MyHC that incrementally increased with the function change groups (Fig. 3) . Across the three LV function change groups, by adjusted ordinal trend test, there were ascending increases in ␣-MyHC (p ϭ 0.012) and ascending decreases in ␤-MyHC (p ϭ 0.007). A similar pattern of ascending decrease was shown for total MyHC (Fig. 4, p ϭ 0 
.014). Because of the progressive increases in ␣-MyHC and decreases in ␤-
MyHC gene expression with increasing LV and RV function, there was also a progressive increase in the percent of ␣-MyHC/total MyHC as function improved (Fig. 4 , ordinal trend test p ϭ 0.026).
For linear regression analysis using change in LVEF as a continuous variable, LVEF change was positively related to change in ␣-MyHC steady-state abundance (r ϭ 0.34, p ϭ 0.023) and to percent ␣-MyHC (r ϭ 0.29, p ϭ 0.045), and negatively related to change in ␤-MyHC (r ϭ Ϫ0.43, p ϭ 0.002), and total MyHC (r ϭ Ϫ0.42, p ϭ 0.003). No other changes in mRNA expression were significantly related to change in LVEF. 
Within-Group Changes
Changes in ␤-Adrenergic Receptor Protein Expression by LV Function Change Group or Linear Regression Analysis of LVEF Change
Between-Group Changes As shown in Figure 5 , by expression-response analysis, there were no differences in the expression of total ␤-, ␤ 1 -, or ␤ 2 -adrenergic receptor protein expression among the three function change groups constructed for the Figure 6 illustrates the changes in ␤-MyHC versus ␣-MyHC, SRCA, ANP, and ␤ 1 -adrenergic receptor mRNA abundance across all subjects and all EF changes. As can be seen, changes in ␤-MyHC and ␣-MyHC are coordinate, with a decreases in ␤-MyHC related to increases in ␣-MyHC. In contrast, changes in ␤-MyHC are unrelated to two other genes ordinarily considered to be part of the fetal gene program, ANP and SRCA. Changes in ␤-MyHC are also unrelated to changes in ␤ 1 -or ␤ 2 -adrenergic receptor mRNA (data not shown).
Coordinate Changes in ␣-, ␤-MyHC mRNA Expression
Discussion
The most common cause of heart failure in the United States is secondary or primary dilated cardiomyopathy, phenotypically characterized by hypertrophy, ventricular chamber dilatation, and decreased contractile function (25) . The alterations in gene expression responsible for dilated cardiomyopathy phenotypes remain unidentified. In terms of contractile dysfunction, leading contenders include changes in components of ␤-adrenergic signal transduction, calciumhandling mechanisms, and contractile proteins (2). For ventricular pathologic hypertrophy, a net increase in contractile protein and sarcomeres through the activation of myocardial growth fetal genes that include ␤-MyHC has been described (6, 7, (26) (27) (28) (29) . The induction of pathologic hypertrophy and the development of contractile dysfunction are interrelated, because the increased expression of ␤-MyHC and associated decreased expression of ␣-MyHC and other genes such as SRCA (28, 29) decrease systolic and diastolic function (2) .
In this study, we utilized the substantial changes in the dilated cardiomyopathy phenotype that occur variably in chronic heart failure patients treated with ␤-blockade or placebo to create a dynamic phenotypic model suitable for investigation of the molecular basis of myocardial failure. The advantage of such a model is considerable, because candidate genes whose expression is not associated with phenotypic modification can be distinguished and eliminated from consideration. Improvement in dilated cardiomyopathy phenotype in response to ␤-blocker therapy involves an increase in velocity of ventricular pressure development (16) , an upward and leftward shift in depressed left (16) and right (20) ventricular function curves indicative of improved intrinsic systolic function, and a decrease in ventricular volume (16) (17) (18) (19) (20) (21) and mass (16, 17, 21) . Primary dilated cardiomyopathy-IDC-was chosen for investigation because IDC is relatively common and its gene expression profile is similar to more common secondary cardiomyopathies (6, 25, 30) . The high response rate of IDC to ␤-blockade plus spontaneous improvement in some subjects in the placebo group led to substantial numbers of subjects exhibiting improvement in LVEF, including 15 subjects 36 subjects with complete ␤-adrenergic receptor protein measurements. For ␤ 2 -receptors, by ANOVA the Improved group had an increased level of expression compared to the Decline/No Change or Marked Improvement group. There were no significant differences between LV function change and receptor protein expression using LVEF change as an ordinal or continuous variable for any receptor type. Figure 5 , the Decline/No Change and Marked Improvement groups exhibited similar within-group increases in ␤ 1 -and total ␤-adrenergic receptor densities, and the Improved group exhibited an increase in ␤ 2 -adrenergic receptor protein expression that was not present in the Decline/No Change or Marked Improvement groups. with a change of more than 17 EF units, a degree of improvement that amounts to normalization or near normalization of left ventricular function. LVEF was used to measure systolic contractile function because the test is readily available and is standardized, and because LVEF is less load-dependent than standard hemodynamic measurements (31) . Moreover, across the three LV function change groups analyzed by ordinal trend test, there were no changes in LV loading conditions that might have confounded the analysis. That is, mean arterial pressure did not change significantly across the three groups, and the trend toward a lower mean pulmonary wedge pressure in the Marked Improvement group would tend to lower, not increase, ejection fraction. Thus, in this study LVEF change should accurately reflect changes in LV systolic function. Because the ejection fraction calculation is heavily influenced by end-diastolic volume, in dilated cardiomyopathies LVEF is also an estimate of the degree of chamber dilatation or remodeling (32) .
Within-Group Changes As shown in
The IDC population investigated in this study exhibited the gene expression abnormalities previously reported by our (1, 4, [6] [7] [8] 30 ) and other (3, 5, 15) laboratories. These changes include components of fetal gene program induction (increased mRNA expression of ANP and ␤-MyHC, decreased expression of ␣-MyHC and SR Ca 2ϩ ATPase), and the consequences of chronic adrenergic activation (downregulation in ␤ 1 -receptor mRNA and protein expression). The question addressed by this study is which of these gene expression abnormalities most closely relates to modifications in dilated cardiomyopathy phenotype measured over a 6-month period in all subjects, regardless of treatment. Because the nature of the relationship between gene expression and any related LVEF change is uncertain and because EF change is unlikely to be linearly related to changes in intrinsic function or degree of pathologic hypertrophy, several types of statistical models were employed.
The results of this study indicate that changes in the mRNA expression of two genes whose regulation is coordinately linked (33) , ␣-and ␤-MyHC, are selectively associated with modifications in ventricular systolic function and remodeling. The expression of ␣-MyHC exhibited a statistically significant progressive increase across ascending LV function change groups, from a negative value in the Decline/No Change group to increasingly positive values in the Improved and Marked Improvement groups. Conversely, ␤-MyHC gene expression exhibited a decrease from a positive change value in phenotypic marker was nonspecifically responding to the general treatment of chronic heart failure. This was confirmed by significant reductions in ANP gene expression within the placebo and carvedilol treatment groups.
There were also no changes in ␤ 1 -adrenergic receptor gene or protein expression or in SRCA gene expression that were systematically associated with changes in ventricular function. In subjects treated with ␤-blocking agents SRCA increases selectively in subjects who exhibit an improvement in LVEF, but spontaneous LVEF responders treated with placebo do not exhibit increases in SRCA (8) . Therefore, in the current analysis that included subjects treated with or without ␤-blockade, there was no relationship between change in SRCA gene expression and change in phenotype. Total ␤-and ␤ 1 -adrenergic receptor protein density increased or tended to increase in all three LV function change groups. This indicates that changes in these molecular myocardial dysfunction candidates can occur in response to heart failure medical treatment, unrelated to modification of ventricular function or remodeling. This was confirmed by significant increases in total ␤-and ␤ 1 -adrenergic receptor protein density within the metoprolol and carvedilol treatment groups.
In this study, ␣-MyHC and ␤-MyHC were coordinately and reciprocally regulated across all changes in LV function. In contrast, two other genes ordinarily considered to be part of the fetal gene program, ANP and SRCA, were not coordinately regulated with ␤-MyHC. Coordinate, reciprocal regulation of cardiac MyHC isoforms in a variety of settings, including pathologic hypertrophy and failure, is well known in small animal models (42) and our data extend these findings to the human heart. The dissociation of regulation of ␤-MyHC from SRCA and ANP indicates that fetal gene regulation is complex, and may be individualized for MyHC isoforms versus other members of this program.
In summary, the data presented in this study indicate that in chronic heart failure patients with a dilated cardiomyopathy phenotype changes in MyHC isogene expression measured in septal endomyocardial biopsy material are closely associated with modification in left ventricular function and chamber remodeling. These associations are specific for MyHC isoform expression, and are not observed for several other molecular changes previously shown to be present in the failing human heart. These observations suggest that modulation of MyHC isoforms may be a therapeutic target for drug development in chronic heart failure, particularly because such treatment should result in cardiac specific effects.
Acknowledgments
This investigation was sponsored by NIH Grants 1R01 HL48013 from the NHLBI, M01-RR00051 and M01-RR00064 from the National Center for Research the Decline/No Change group to progressively more negative values in the Improved and Marked Improvement groups. If translated into proportional changes in protein expression (34) , such changes in MyHC isogene expression could potentially improve intrinsic systolic and diastolic function (35) because the ␣-MyHC isoform has a much higher myosin ATPase activity than the ␤-isoform, resulting in a faster velocity of shortening and rate of crossbridge cycling (26, 27, 35) . In rodent (35) (36) (37) and rabbit (38) models of pathologic hypertrophy and myocardial failure, coordinate decreases in ␣-MyHC and increases in ␤-MyHC mRNA and protein expression are associated with a reduction in velocity of shortening and other measures of systolic function.
Although in the current study the small amounts of starting material precluded measurement of ␣-and ␤-MyHC protein, in gram quantities of failing explanted human left ventricular myocardium changes in gel electrophoresis-measured MyHC isoforms are directionally similar to changes in mRNA (34) . However, in human ventricular myocardium the absolute expression of ␣-MyHC protein is much less than its mRNA expression (32, 39) . For example, in nonfailing left ventricles ␣-MyHC protein expression is 5-10% of total MyHC, versus 25-30% for mRNA (34) . Although the protein expression of ␣-MyHC decreases to near zero in failing hearts (34, 39) , it is unclear if such a small absolute change can account for a decrease in intrinsic contractile function. In favor of such small changes being functionally significant are the observations that (1) in model systems small amounts (ϳ10%) (40) or changes (37) of ␣-MyHC have relatively large effects on force development and (2) recent data from our laboratory demonstrating that human cardiac ␣-MyHC has greater (relative to ␤-MyHC) specific myosin and myofibrillar ATPase activities than has been in reported in rat or rabbit hearts (K. Nunley et al., submitted). Thus an increase in percent ␣MyHC isoform expression is a molecular change that could causally relate to improved function. Alternatively, changes toward normal in MyHC isoforms could simply be a molecular marker of de-induction of the fetal gene program, with other components accounting for the actual improvement in function.
Similarly, the progressive decrease in total MyHC (␣-MyHC ϩ ␤-MyHC) gene expression with increasing LVEF (and decreasing end diastolic volume) (32) is a molecular measure of reverse remodeling; MyHC is a major structural protein of the myocardial contractile element (41) . As a molecular index of reverse remodeling, in the current study changes in total MyHC or ␤-MyHC appeared to be superior to the indirect hypertrophic marker ANP, because total or ␤-MyHC but not ANP expression exhibited an incremental decline as remodeling progressively decreased. ANP gene expression decreased or tended to decrease in all LV function/diastolic volume change groups, indicating that this molecular
